Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,290.00
-130.00 (-2.40%)
Oct 30, 2025, 3:30 PM KST
-2.40%
Market Cap508.03B
Revenue (ttm)1.87B
Net Income (ttm)-20.08B
Shares Out96.04M
EPS (ttm)-234.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume372,198
Average Volume461,619
Open5,400.00
Previous Close5,420.00
Day's Range5,270.00 - 5,420.00
52-Week Range4,325.00 - 8,865.00
Beta0.91
RSI43.44
Earnings DateAug 14, 2025

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements

News

There is no news available yet.